CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 72 enrolled
Drug / intervention
cetuximabbiological
Likely dose
Not stated in record
Key inclusion· 7
  • ✓Histologically or cytologically confirmed bronchoalveolar carcinoma (BAC) or adenocarcinoma of the lung with BAC features, Stage IIIB (with pleural/pericardial effusion), Stage IV, or recurrent disease
  • ✓Measurable disease
  • ✓Tumor tissue available from biopsy
  • ✓Age 18 and over
Key exclusion· 9
  • ✕Untreated brain metastases (stable metastases ≥4 weeks after brain radiotherapy allowed)
  • ✕Prior cetuximab or other EGFR inhibitors (gefitinib, erlotinib)
  • ✕Prior allergic reaction to chimerized or murine monoclonal antibody therapy
  • ✕Documented presence of human anti-mouse antibodies

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00103207
NCT00103207Phase 2Completed
CompareCT.gov

Phase II Study of C225 (Cetuximab) for the Treatment of Patients With Advanced Bronchioalveolar Carcinoma (BAC) or Adenocarcinoma With BAC Features

Eastern Cooperative Oncology Group·interventional·Posted Feb 8, 2005·Updated Jun 28, 2023

In Brief

A Phase 2 clinical trial evaluating cetuximab for Lung Cancer. Completed, enrolled 72 participants across 157 sites.

Detailed Summary

RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. PURPOSE: This phase II trial is studying how well cetuximab works in treating patients with recurrent or stage IIIB or stage IV lung cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLung Cancer
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

Phase 2CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 8, 2005
Enrollment StartOct 13, 2005
Primary CompletionApr 1, 2010
Study CompletionAug 1, 2012
TodayJul 2, 2026
Enrollment to primary: 4.5 yearsPosted 21.4 years ago

Interventions

cetuximabbiological